Fig. 2: TMB score varies by biopsied site.

a Comparison of TMB score distributions in metastases and primary tissues. The average difference and significance computed from a multivariate linear model are shown. Patient counts for each cancer type and biopsy site are provided in Fig. 1b and Supplementary Data 1. b Distribution of TMB scores across biopsied sites in patients diagnosed with NSCLC. Patient counts for each cancer type and biopsy site are provided in Fig. 1b and Supplementary Data 1. c Distribution of the fraction of NSCLC patients assessed as TMB-high as a function of the biopsied sites used for genomic testing. TMB-high cutoff ≥10 mut/Mb. Patient counts for each cancer type and biopsy site are provided in Fig. 1b and Supplementary Data 1. d Forest plots from multivariate linear models testing the association between the biopsied site (rows) and TMB scores across different cancer types (columns). Each cancer type is modeled independently. Reference tissues used for modelling are represented by a dark gray box with a dot at 0. The dots and color gradient represent the average difference between the tissue and a reference tissue. The horizontal lines represent the 95% confidence interval of the average difference. The transparency of the box colors is adjusted according to the significance (p value) of the association. Patient counts for each cancer type and biopsy site are provided in Fig. 1b and Supplementary Data 1. e Heatmap showing differences of percentage of specimens assessed as TMB-high (≥10 mut/Mb) between the biopsied site (rows) and reference tissue, across different cancer types (columns). The transparency of the box colors is adjusted according to the significance (p value) of the difference assessed by chi-square test. Patient counts for each cancer type and biopsy site are provided in Fig. 1b and Supplementary Data 1.